Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension

被引：0

作者：

van der Heijde, Desiree ^{[1
]}

Deodhar, Atul ^{[2
]}

Maksymowych, Walter ^{[3
]}

Sieper, Joachim ^{[4
,5
,6
]}

Van den Bosch, Filip ^{[7
]}

Kim, Tae-Hwan ^{[8
]}

Kishimoto, Mitsumasa ^{[9
]}

Ostor, Andrew ^{[10
,11
]}

Combe, Bernard ^{[12
]}

Sui, Yunxia ^{[13
]}

Duan, Yuanyuan ^{[14
]}

Chu, Alvina D. ^{[14
]}

Song, In-Ho ^{[14
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Rheumatol, Meerssen, Netherlands

[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[3] Univ Alberta, Dept Med, Edmonton, AB, Canada

[4] Charite Univ Med Berlin, Dept Gastroenterol Infectiol & Rheumatol Includin, Berlin, Germany

[5] Free Univ Berlin, Berlin, Germany

[6] Humboldt Univ, Berlin, Germany

[7] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium

[8] Hanyang Univ Hosp Rheumat Dis, Seoul, South Korea

[9] Kyorin Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan

[10] Monash Univ, Cabrini Hosp, Malvern, Australia

[11] Emertius Res, Malvern, Australia

[12] Montpellier Univ, Montpellier, France

[13] AbbVie, N Chicago, IL 60064 USA

[14] AbbVie Inc, N Chicago, IL USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0924

引用

页码：1925 / 1928

页数：4

共 50 条

[1] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
van der Heijde, Desiree
Deodhar, Atul
Maksymowych, Walter P.
Sieper, Joachim
van den Bosch, Filip
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Ostor, Andrew
Combe, Bernard
Sui, Yunxia
Duan, Yuanyuan
Chu, Alvina D.
Song, In-Ho
INTERNAL MEDICINE JOURNAL, 2022, 52 : 26 - 26
[2] Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Deodhar, Atul
van der Heijde, Desiree
Sieper, Joachim
Van den Bosch, Filip
Maksymowych, Walter
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Ostor, Andrew
Combe, Bernard
Sui, Yunxia
Wang, Xin
Chu, Alvina D.
Song, In-Ho
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[3] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 1-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
Deodhar, A.
Van der Heijde, D.
Sieper, J.
Van den Bosch, F.
Maksymowych, W. P.
Kim, T. H.
Kishimoto, M.
Ostor, A.
Combe, B.
Sui, Y.
Wang, X.
Chu, A.
Song, I. H.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 85 - 86
[4] Efficacy and Safety of Upadacitinib in Patients With Active Ankylosing Spondylitis: 1-Year Results From a Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension
Maksymowych, Walter
van der Heijde, Desiree
Sieper, Joachim
van den Bosch, Filip
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Ostor, Andrew
Combe, Bernard
Sui, Yunxia
Wang, Xin
Chu, Alvina
Song, In-Ho
Deodhar, Atul
JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1122 - 1122
[5] Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
van der Heijde, Desiree
Deodhar, Atul
Maksymowych, Walter P.
Sieper, Joachim
Van den Bosch, Filip
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Ostor, Andrew J.
Combe, Bernard
Sui, Yunxia
Duan, Yuanyuan
Wung, Peter K.
Song, In-Ho
RMD OPEN, 2022, 8 (02):
[6] Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension
Deodhar, Atul
van der Heijde, Desiree
Sieper, Joachim
Van den Bosch, Filip
Maksymowych, Walter P.
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Ostor, Andrew
Combe, Bernard
Sui, Yunxia
Chu, Alvina D.
Song, In-Ho
ARTHRITIS & RHEUMATOLOGY, 2022, 74 (01) : 70 - 80
[7] Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
van der Heijde, Desiree
Song, In-Ho
Pangan, Aileen
Deodhar, Atul
Van den Bosch, Filip
Maksymowych, Walter P.
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Everding, Andrea
Sui, Yunxia
Wang, Xin
Chu, Alvina D.
Sieper, Joachim
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[8] Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study
Boonen, Steven
Lorenc, Roman S.
Wenderoth, Dietrich
Stoner, Karen J.
Eusebio, Rachelle
Orwoll, Eric S.
BONE, 2012, 51 (03) : 383 - 388
[9] A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis
Peters, Eric
Chou, Richard C.
Rozzo, Stephen J.
Yao, Siu-Long
Fructuoso, Ferran Jose Garcia
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 (05) : 223 - 229
[10] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
Van der Heijde, D.
Baraliakos, X.
Sieper, J.
Deodhar, A.
Inman, R.
Kameda, H.
Zeng, X.
Sui, Y.
Bu, X.
Pangan, A.
Wung, P.
Song, I. H.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 402 - 403

← 1 2 3 4 5 →